Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 11/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874177 | 0.88 | ADAMTS5 (0.37) | ADAMTS5ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL2872659 | 0.86 | GRIA1 (0.46) | ADAMTS5MMP13ADAMTS4MMP2MMP3 | |
| SCHEMBL2873543 | 0.85 | ADAMTS5 (0.51) | ADAMTS5ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL2871225 | 0.83 | ADAMTS5 (0.36) | ADAMTS5ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL2872035 | 0.82 | MKNK1 (0.38) | ADAMTS5MMP13ADAMTS4MMP2MMP3 | |
| SCHEMBL2872048 | 0.82 | KMT2A (0.42) | POLBMAPTLMNASMN1; SMN2 | |
| SCHEMBL2866828 | 0.82 | MAPT (0.46) | POLBTP53MAPTLMNA | |
| SCHEMBL2874365 | 0.82 | FFAR1 (0.40) | ADAMTS5ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL2869573 | 0.82 | PTGS2 (0.37) | ADAMTS5ADAM17MMP13ADAMTS4MMP2 | |
| SCHEMBL2874303 | 0.81 | MCHR1 (0.41) | ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | claimed |
| EP-1542977-B1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | EP | claimed |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | claimed |
| EP-1542977-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | AstraZeneca AB (SE) | 2005-06-22 | — | — | EP | claimed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | claimed |
| US-7662845-B2 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| EP-1542977-B1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| US-20060276524-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1542977-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | AstraZeneca AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276524-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | MMP12, MMP13, MMP9 | ADAMTS5 40/4885ADAM17 30/4885MMP13 2/4885 |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | MMP12, PDE12, MMP13 | ADAMTS5 74/4885ADAM17 37/4885MMP13 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.